16^th International Conference on Pharmaceutical Chemistry August 17-18, 2020 London, UK

Research and Development can be defined as innovative and experimental work undertaken on a systematic basis to increase the stock of knowledge including search of new molecules, synthesis and modification of known molecules and some methods to increase production rate by adopting diverse techniques. Superior quality R&D work requires an excellent back up from what are called the support functions. These include analytical, information services and technology, intellectual property and regulatory affairs. These are some of the main considerations in Pharmaceutical Technology and for the development of new drug candidates. The management of these functions, especially the laboratory based analytical service, requires many of the skills associated with core R&D and will therefore not be treated separately in any detail, except to point out their relationship and role within the organization.

• Challenges in Pharmaceutical Formulations
•  Scope of Pharmaceutical Research
• Pharmaceutical Research & Development
• Pharmaceutical Packaging and labeling
• Pharmaceutical industry
• Bioinformatics and Computational Biology
• Pharmaceutical Technology Assessment
• Quality assurance

Chemogenomics is an emergent discipline that combines the latest tools of genomics and chemistry and applies in the discovery of novel drug molecules thereby to target drug discovery. Because of the almost infinite number of drug-like organic molecules, this is an impossible task. Chemogenomics, on the other hand can be defined as the investigation of classes of compounds or related libraries. These compounds are meant to work against families of functionally related proteins in the protein structure. Chemogenomics also deals with the chemical-biological interactions and their systematic analysis. The current meeting of chemistry conferences will be a multinational gathering and present majorareas such as Medicinal Chemistry, Pharmaceutical Sciences, Pharmaceutical Chemistry, Pharmaceutical Technology.

• Biomolecules
•  Metal Complexes creation
• Asymmetric synthesis
• Organometallic chemistry
•  Nucleotide chemistry
• Chemogenomics and Chemical Biology for Target Identification and Validation
• Assemblies of macrolide-mimetics
• Spiro– medium- and large(macro) heterocyclic systems
• Isosteric replacements of amino acids, di-/tri-peptides

Solid-state pharmaceutical chemistry envelops a wide scope of concentrates on pharmaceutical solids including (1) assurance of the physical properties of polymorphs and solvates, (2) physical changes among polymorphs and solvates, (3) chemical responses in the solid state, and (4) solid-solid responses which happen in pharmaceutical preparations. Recent advances in this field incorporate improved comprehension of crystallization processes, improved comprehension of the requirement for characterization of polymorphs and solvates for both control and administrative purposes, and a superior comprehension of the mechanisms of solid state degradations and solid-solid reactions.

Organic chemistry  is the scientific study of the structure, properties, composition, reactions, and synthesis of organic compounds that by definition contain carbon. Organic chemistry is the scientific study of the structure, properties, composition, reactions, and synthesis of organic compounds that by definition contain carbon. Pharmaceutical heavily relies on medical world as it centers around medicine and other health related compound. A pharmacist should have sufficient knowledge of organic chemistry as the basis of drug prescription.

Pharmacovigilance (PV) is defined as the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem. WHO established its Programme for International Drug Monitoring in response to the thalidomide disaster detected in 1961. Together with the WHO Collaborating Centre for International Drug Monitoring, Uppsala, WHO promotes PV at the country level. At the end of 2010, 134 countries were part of the WHO PV Programme. The aims of PV are to enhance patient care and patient safety in relation to the use of medicines; and to support public health programmes by providing reliable, balanced information for the effective assessment of the risk-benefit profile of medicines.

The discovery of candidate drug targets is challenging, requiring the rapid development of techniques to identify the difference genomic profiling in disease and normal conditions, which will facilitate the understanding of the disease mechanism and the development of potential drugs for disease treatment. Medicinal chemistry has increasingly employed microarrays to identify both key target genes and gene networks that can regulate the effectiveness of drugs. As compared with all the other phases in drug discovery, this stage is complex by the fact that the identified drug target must mollify a variety of standards to permit development to the next step. For example, the target must be selectively present in the pathogen, i.e. medicinal chemistry along with coding genes of drug design target that are preserved across different pathogens and have no human homologs and therefore they represent striking target candidates for new broad-spectrum drugs. The current meeting of chemistry conferences will be a multinational gathering and present majorareas such as Medicinal Chemistry, Pharmaceutical Sciences, Pharmaceutical Chemistry, Pharmaceutical Technology.

• Fragment-Based Drug Discovery
• Macrocyclics & Constrained Peptides
• Biophysical Approaches for Drug Discovery
• Small Molecules for Cancer Immunotherapy
• Inflammation Inhibitors
• Protein-Protein Interactions
• GPCR-Targeted Drug Design
• Blood-Brain Penetrate Inhibitors
• Kinase Inhibitor Chemistry

In the drug discovery and drug development of a new drug, different terms are assigned to the substances that are studied at different steps in the process. Only if a substance fulfils the requirements for a certain level is it subjected to testing on the next level. The process starts with a compound which is a chemical substance of defined chemical structure and purity. There are many strategies developed in Medicinal Chemistry in the recent years for the development of new drug candidates. Compounds that show specific binding properties and are active are referred to as ‘hits’ and are further validated; this includes verifying their chemical identity and purity and determining their binding properties in one or more secondary assays. The current meeting of chemistry conferences will be a multinational gathering and present majorareas such as Medicinal Chemistry, Pharmaceutical Sciences, Pharmaceutical Chemistry, Pharmaceutical Technology. 

• Immuno-oncology
• Small-molecule targeting of RNAs
• Preventative Toxicology
• Molecules with predictable in vivo and safety profiles
• Phenotypic screening
• SBDD Case studies
• Macrocyclic compounds

Modern drug research and development (R&D) has experienced remarkable changes as technological and scientific developments in the past years have dramatically changed the pharmaceutical innovation process. Well-established strategies, such as high-throughput screening (HTS), have progressively been applied in association with novel techniques founded on genomics, molecular and structural biology and molecular modeling.

• Targeted protein degradation / PROTACs
• DNA Encoded Libraries
• Hit-to-Lead Optimization
• Predictive Toxicology – Improving Compound Safety
• Optimizing Outsourcing Activities
• Artificial Intelligence in Medicinal Chemistry

Traditionally, “drug delivery” was a specialization in pharmacy for formulations of drugs. However, it is natural that organic, medicinal, materials, and nano chemistry have now become deeply involved in the development of drug delivery systems. These approaches have led to the creation of drug conjugates that are new chemical entities. The use of functional carbon nanotubes as well as designed polymers as a vehicle for drug delivery is a novel approach to drug discovery. Medicinal chemistry and pharmaceutical chemistry are disciplines at the intersection of chemistry, especially synthetic organic chemistry, and pharmacology and various other biological specialties, where they are involved with design, chemical synthesis and development for market of pharmaceutical agents, or bio-active molecules (drugs). The current meeting of chemistry conferences will be a multinational gathering and present majorareas such as Medicinal Chemistry, Pharmaceutical Sciences, Pharmaceutical Chemistry, Pharmaceutical Technology.

•  Drug Discovery Chemistry – where are we heading
• Target Validation using Medicinal Chemistry tools
• Optimizing hit to lead optimization quality and timescale
• Best Practice Case Studies
• Data for decision making
• Protein Degradation Strategies
• Future of Medicinal Chemistry

Pharmacokinetics is currently defined as the study of the time course of drug absorption, distribution, metabolism, and excretion. Clinical pharmacokinetics is the application of pharmacokinetic principles to the safe and effective therapeutic management of drugs in an individual patient. Primary goals of clinical pharmacokinetics include enhancing efficacy and decreasing toxicity of a patient’s drug therapy. The development of strong correlations between drug concentrations and their pharmacologic responses has enabled clinicians to apply pharmacokinetic principles to actual patient situations.

Pharmacodynamics refers to the relationship between drug concentration at the site of action and the resulting effect, including the time course and intensity of therapeutic and adverse effects. The effect of a drug present at the site of action is determined by that drug’s binding with a receptor.

• Pharmacokinetic parameters
• Absorption of drugs
• Distribution of drugs
• Biotransformation/metabolism
• Excretion of drugs
• Pharmacodynamics

The rational development of new drugs is a complex process involving a myriad of different disciplines. In nearly all of these, computational tools serve to guide the design decisions, ultimately speeding up and reducing the cost of development. Drug design and the synthesis of new drug molecules is one of the important aspect in medicinal chemistry and it is one of the keytopics discussed at Medicinal Chemistry Conferences. In the area of medicinal chemistry, computational methods are applied both to identify new starting points and to guide the further development of promising substances.

• Aggressive Bond Disconnections in Total Synthesis
• Chemical Probes for Characterizing Biology
• Synthetic Biology for Natural Products
• Advances in Drug Discovery
• Natural Product Discovery and Biosynthesis
• Combining Synthesis and Biosynthesis to Construct Complex Molecules
• New Directions in Antibiotic Discovery and Development
• Accessing Complex Molecules
• Structure-biodegradability relationship
• Diversity-Oriented Synthesis

The synthesis of each molecule was first carried out on a small scale (probably milligrams) in the laboratory, followed much later by development of safe, efficient, and scalable methods to provide kilograms of active pharmaceutical ingredient (API) that was incorporated into dosage forms for administration to patients. It is critical to point out that an early step in the complex process of drug discovery was the synthesis of a molecule that tested a hypothesis faced by the project team. This required a medicinal chemist to use organic chemistry training and experience to conceive of a compound and then employ appropriate reactions to furnish the desired target and synthesize a suitable number of derivatives to optimize the spectrum of properties associated with drug like candidates. The current meeting of chemistry conferences will be a multinational gathering and present majorareas such as Medicinal Chemistry, Pharmaceutical Sciences, Pharmaceutical Chemistry, Pharmaceutical Technology.

•  Medicinal chemistry
• Drug discovery
• Total synthesis of natural products
• Heterocyclic compounds
• Synthesis and functional properties of molecules
• Asymmetric synthesis
• Green chemistry
• New reagents, strategies, catalysts and concepts for organic synthesis
• Mechanistic organic chemistry
• Computational chemistry
• Supramolecular chemistry

Nano medicine is simply the nanotechnology applications in a healthcare setting and the majority of benefits that have already been seen involve the use of nanoparticles to improve the behavior of drug substances and in drug delivery. Today, nanomedicine conferences are used globally to improve the treatments and lives of patients suffering from a range of disorders including ovarian and breast cancer, kidney disease, fungal infections, elevated cholesterol, menopausal symptoms, multiple sclerosis, chronic pain, asthma and emphysema. Nanomedicine has the potential to develop radical new therapies based on an unprecedented control over both intracellular processes and the extracellular environment at the nanometer scale. To create precise solutions for intricate medical challenges in the area of wound healing, tissue regeneration and mitochondrial disease physical scientists, medical doctors, and industrial partners, work closely in the Radboud Nanomedicine Alliance. The National Nanotechnology Initiative expects new commercial applications in the pharmaceutical industry that may include advanced delivery systems, new therapies, and in vivo imaging.

• Scope of nanomedicine
• Novel drugs to nano drugs
• Nanomedicine for other disease
• Nanomedicine for gastrointestinal tract (GI) diseases
• Nanomedicine for CNS
• Nanomedicine for blood disorders
• Nanomedicine for lung diseases
• Nanomedicine for cardiovascular diseases
• Future aspects of nanomedicine
• Nanodrugs for herbal medicines and cosmetics

From drug synthesis to quality control (QC) monitoring of over-the-counter medications, metals are found in all phases of the drug development process. Many metal-based products are used as imaging agents, and metals are used in the synthesis of drug substances, as excipients in tablets, capsules and liquids. In addition, trace metals can arise from the equipment used to manufacture a drug substance or compound. Because of the prevalence of metals associated with the drug development and manufacturing process, various atomic and emission-based techniques are often used to help fully characterize pharmaceutical products

Pharmacovigilance (PV or PhV), also known as drug safety, is the pharmacological science relating to the collection, detection, assessment, monitoring, and prevention of adverse effects with pharmaceutical product. The etymological roots for the word "pharmacovigilance" are: pharmakon (Greek for drug) and vigilare (Latin for to keep watch). As such, pharmacovigilance heavily focuses on adverse drug reactions, or ADRs, which are defined as any response to a drug which is noxious and unintended, including lack of efficacy (the condition that this definition only applies with the doses normally used for the prophylaxis, diagnosis or therapy of disease, or for the modification of physiological disorder function was excluded with the latest amendment of the applicable legislation). Medication errors such as overdose, and misuse and abuse of a drug as well as drug exposure during pregnancy and breastfeeding, are also of interest, even without an adverse event, because they may result in an adverse drug reaction.

Cosmetovigilance is the ongoing and systematic monitoring of the safety of cosmetics in terms of human health. The aim is to detect adverse effects of cosmetic products, and to prevent adverse effects by taking appropriate measures. Regulations for cosmetic products primarily address the safety of products that may be used by large populations of healthy consumers. The identification and analysis of adverse effects related to cosmetic products is a process that is currently still, to a large extent, industry driven. It is the responsibility of manufacturers to determine that products and ingredients are safe before they are marketed, and then to collect reports of adverse reactions.

Broadly defined, the discipline of bioorganic chemistry seeks an understanding of biological processes through the tools and principles of organic chemistry. Bioorganic chemistry can be defined as a multifaceted field which has its historical roots in detailed mechanistic studies of enzyme along with coenzyme models. The field of bioorganic chemistry currently focuses more on the trending topics like molecular recognition, encompassing mechanistic investigations of enzymes themselves, drug design. It also deals with study of drug action, problems in biosynthesis, protein engineering, molecular evolution, supramolecular chemistry, and many other allied subjects.

• Structural and in-Silico Chemistry
• Chemical Biology for Drug Discovery
• Pain Medications and their SAR
• Recent Advances in Targeting Autophagy
• Advances in Synthesis and Medicinal Chemistry
• Photo-redox Catalysis

Phytochemistry is in the study of phytochemicals in plants and other natural sources. Phytochemicals are chemicals derived from plants. In other words the terms are often used to describe the large number of primary and secondary metabolic compounds found in plants. Phytochemicals have properties such as protection against insect attacks and diseases. They also exhibit a number of protective functions for human beings also.

• Traditional Medicine
• Clinical Pharmacognosy
• Aromatic Medicinal Plants
• Marine Drugs
• Applied Plant Sciences

Medico-Marketing focusses on exchange of drug information among drug manufacturing company and the recommending doctor, Nurse, Pharmacist or with the end user. The intention behind this data exchange is to describe the Pharmaceutical Company’s products and how it will benefit the patient community in diagnosis or management of the human ailments.

The recent changes in the way that synthetic chemistry is practiced in this environment center around new scientific advances in synthetic techniques and modern technologies for rational drug design, combinatorial chemistry, automated synthesis, and compound purification and identification. In addition, with the beginning of high-throughput screening, we are now dealing with many targets being screened and many other hits that are being evaluated. However, success in the discovery of new drug molecules requires more and more skilled medicinal chemists to make the accurate choices with the insights gathered from interactions with computational chemists along with the insights from structural biologists, about which “hits” are likely to play out as true “lead” structures that will meet the plethora of hurdles that any drug candidate must surmount.

• Virtual Screening
• Target Structure-Based Design
• QSAR (Quantitative Structure-Activity Relationship)
• Fragment-Based Drug Design

The pharmaceutical industry channels an important proportion of total research in most developed countries. In Europe, for example, it represents about 13% of total R&D. In recent years, pharmaceutical companies have been accused of devoting their resources mainly to minor improvements over existing medications that require short clinical trials and have a small risk of not being approved. The support functions were an integral part of a large company’s R&D function but nowadays they are most likely to be outsourced under contract to external organizations specializing in a specific service, especially if these activities are not seen to offer a competitive advantage to the company. Medicinal chemistry and pharmaceutical chemistry are disciplines at the intersection of chemistry, especially synthetic organic chemistry, and pharmacology and various other biological specialties, where they are involved with design, chemical synthesis and development for market of pharmaceutical agents, or bio-active molecules (drugs).

• Recent Development of Pharmaceutical Materials
• Recent developments In Pharmaceutics & Biopharmaceutics
• Advancements in Pharmaceutical Biotechnology
• Approaches in Pharmaceutical Nanotechnology
• Innovations in Pharmaceutical Technology\
• Advancements in Pharmaceutical Manufacturing
• Development in Pharmaceutical Engineering
• Pharmacological Technology advances